J. Carter

发表

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

P. Elsbernd, J. Carter, 2021, Biologics : targets & therapy.

The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations

D. Wingerchuk, J. Carter, Cristina Valencia-Sanchez, 2019, Multiple sclerosis.

Ventilatory dysfunction in multiple sclerosis.

J. Noseworthy, J. Carter, J. H. Noseworthy, 1994, Clinics in chest medicine.

Steroid-responsive encephalopathy associated with autoimmune thyroiditis.

B. Boeve, R. Caselli, G. Hunder, 2006, Archives of neurology.

Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions

J. Parisi, B. Weinshenker, C. Lucchinetti, 2015, Neurology.

Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review.

D. Wingerchuk, P. Elsbernd, J. Carter, 2020, Multiple sclerosis and related disorders.

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene

T. Fife, E. Bord, Shruti P. Agnihotri, 2014, Neurology.

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.

B. Weinshenker, C. Lucchinetti, O. Kantarci, 2009, Archives of neurology.

Treatment of Neuromyelitis Optica With Mycophenolate Mofetil

B. Weinshenker, C. Lucchinetti, O. Kantarci, 2009 .

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders

Jeffrey A. Cohen, R. Kinkel, J. Carter, 1999, Journal of Neuroimmunology.

Are Corticosteroids Efficacious for Preventing or Treating Neutralizing Antibodies in Multiple Sclerosis Patients Treated With Beta-Interferons?: A Critically Appraised Topic

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2010, The neurologist.

Rational clinical immunotherapy for multiple sclerosis.

B. Weinshenker, J. Noseworthy, S. Hunter, 1997, Mayo Clinic proceedings.

Disease Modifying Therapies for Multiple Sclerosis

J. Carter, 1995 .

Immunosuppressive treatment of multiple sclerosis.

M. Rodriguez, J. Carter, M. Rodriguez, 1989, Mayo Clinic proceedings.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

D. Wingerchuk, Dean M Wingerchuk, Jonathan L Carter, 2014, Mayo Clinic proceedings.

26-year-old man with hyperpigmentation of skin and lower extremity spasticity.

B. Crum, J. Carter, 1997, Mayo Clinic proceedings.

Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.

D. Wingerchuk, J. Carter, Greg M Thaera, 2014, Multiple sclerosis and related disorders.

Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double‐blind, placebo‐controlled trial

F. Lublin, G. Birnbaum, J. Carter, 1994, Neurology.

An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis

J. Carter, Cristina Valencia-Sanchez, 2020, Expert opinion on pharmacotherapy.

Status of neurology medical school education

R. Shin, J. Safdieh, R. Isaacson, 2014, Neurology.

MRI changes in status epilepticus

J. Sirven, J. Drazkowski, R. Zimmerman, 2003, Neurology.

The contemporary spectrum of multiple sclerosis misdiagnosis

Gregory F. Wu, B. Weinshenker, A. Cross, 2016, Neurology.

Do Cannabinoids Reduce Multiple Sclerosis-Related Spasticity?

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2009, The neurologist.

Management of impairment, disability, and handicap due to multiple sclerosis.

J. Carter, D. Rohe, K. Stolp‐Smith, 1997, Mayo Clinic proceedings.

Aspirin is Unlikely to Have A Clinically Meaningful Effect on Multiple Sclerosis-Related Fatigue: Data From a Randomized Controlled Trial (P7.245)

Moses Rodriguez, M. Keegan, D. Wingerchuk, 2014 .

Autonomic symptom burden is associated with MS-related fatigue and quality of life.

D. Wingerchuk, J. Carter, B. Goodman, 2015, Multiple sclerosis and related disorders.

Not every patient with multiple sclerosis should be treated at time of diagnosis.

B. Weinshenker, C. Lucchinetti, Moses Rodriguez, 2006, Archives of neurology.

Cerebral enhancement in MOG antibody-associated disease

J. Tillema, D. Wingerchuk, P. Morris, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

Immunosuppression with high‐dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: Cumulative 6‐year experience in 164 patients

D. Hafler, J. Orav, D. Dawson, 1988, Neurology.

The immunopathology of multiple sclerosis

J. Carter, M. Rodriguez, 1991 .

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination.

J. Parisi, R. Caselli, C. Lucchinetti, 2011, Archives of neurology.

Cumulative Experience with High‐Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis

H. Weiner, D. Hafler, J. Orav, 1988, Annals of the New York Academy of Sciences.

Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.

H. Weiner, D. Hafler, D. Dawson, 1987, Rivista di neurologia.

Peripheral sensory abnormalities in patients with multiple sclerosis

C. Krarup, J. Shefner, J. Carter, 1992, Muscle & nerve.

Autoimmune encephalopathies

J. Honnorat, J. Carter, 2013, Neurology.

Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: Critical Role of Retina Specialists

Odette M. Houghton, R. Dhamija, J. Carter, 2023, Journal of vitreoretinal diseases.

Steroid-responsive encephalopathy associated with autoimmune thyroiditis.

B. Boeve, R. Caselli, G. Hunder, 2006, Archives of neurology.

Do Cannabinoids Reduce Multiple Sclerosis-Related Spasticity?

B. Demaerschalk, D. Wingerchuk, K. Wellik, 2009, The neurologist.